Sagimet Biosciences Inc. 8-K

What Happened

• On April 27, 2026, Sagimet Biosciences, Inc. (SGMT) filed a Form 8-K furnishing unaudited preliminary financial information for the quarter ended March 31, 2026. The company estimates its cash, cash equivalents and marketable securities totaled approximately $104.5 million as of March 31, 2026. This amount is preliminary, unaudited, prepared by management and subject to change after completion of closing procedures.
• The company also updated an investor slide presentation and issued a press release on April 27, 2026 (filed as Exhibits 99.1 and 99.2). The firm’s independent auditor, KPMG LLP, has not audited or reviewed the preliminary figures and therefore expresses no assurance on them.

Key Details

• Preliminary cash, cash equivalents and marketable securities: approximately $104.5 million (unaudited) as of March 31, 2026.
• Date of filing and disclosures: April 27, 2026 (8-K filing; Exhibits 99.1 investor presentation and 99.2 press release).
• Preliminary data prepared by management; subject to change after financial close and review. KPMG LLP has not audited or reviewed this preliminary information.
• Company cautions this is not a substitute for GAAP financial statements and may not reflect final quarter-end balances.

Why It Matters

• Cash and marketable securities are a key indicator of a biotech company’s runway and ability to fund operations and development programs; the $104.5M preliminary balance gives investors a current snapshot of liquidity.
• Because the figure is unaudited and preliminary, investors should treat it as an estimate and review the updated investor presentation and press release for context and any strategic updates. Watch for the company’s finalized quarterly results or subsequent filings for audited numbers and more complete financial details.